Re: Screening and prostate cancer mortality: Results of the European Randomised study of screening for prostate cancer (ERSPC) at 13 years of follow-up

European Urology

Volumn 67, Issue 1, 2015, Pages 175-

  Bill Axelson, Anna ^a   Bratt, Ola ^b,c  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER MORTALITY; CANCER SCREENING; FOLLOW UP; HUMAN; NOTE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); MALE; MORTALITY; PROSTATIC NEOPLASMS;

HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84926016586     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.09.048     Document Type: Note

References (5)

1. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. In press. http://dx.doi.org/10.1016/S0140-6736(14)60525-0
2. G.L. Andriole, E.D. Crawford, and R.L. Grubb III Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up J Natl Cancer Inst. 104 2012 125 132
3. V.A. Moyer U.S. Preventive Services Task Force Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 157 2012 120 134
4. S. Carlsson, A.J. Vickers, and M. Roobol Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review J Clin Oncol 30 2012 2581 2584
5. C. Arsov, N. Becker, and B.A. Hadaschik Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial Eur Urol 64 2013 873 875